New combination trial with lirilumab in hemato-oncology

• 8 trials ongoing with lirilumab in multiple indications and combinations

• 5 combination trials ongoing in hemato-oncology

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) announced that a new trial performed by the MD Anderson cancer center started, testing a combination of nivolumab, lirilumab and 5-azacytidine for the treatment of patients with Myelodysplastic Syndrome (MDS). 

This is the third trial with lirilumab supported by Bristol-Myers Squibb and performed by the MD Anderson cancer center in 2015, after the opening of one trial testing the combination of lirilumab and 5-azacytidine in relapsed/ refractory AML and another trial testing the combination of lirilumab and rituximab in relapsed/ refractory or high-risk untreated CLL.

These new trials bring to 8 the number of trials performed with lirilumab, testing a broad range of solid and hematological cancer indications, multiple rationales and combinations with cytotoxic antibodies, checkpoint inhibitors and chemotherapy. See clinicaltrials.gov